Clinical Trials Logo

Stage IIIA Breast Cancer clinical trials

View clinical trials related to Stage IIIA Breast Cancer.

Filter by:

NCT ID: NCT01151449 Terminated - Clinical trials for Stage IV Breast Cancer

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Start date: June 2010
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with advanced, metastatic, or recurrent triple negative invasive breast cancer. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01140282 Completed - Clinical trials for Stage IIIA Breast Cancer

Exercise Program for Early Breast Cancer Survivors

Start date: May 21, 2012
Phase: N/A
Study type: Interventional

Rationale: Exercise therapy may improve the quality of life of breast cancer survivors. Purpose: This randomized clinical trial studies exercise therapy and quality of life in postmenopausal early breast cancer survivors receiving aromatase inhibitor therapy.

NCT ID: NCT01113554 Completed - Clinical trials for Stage IV Breast Cancer

Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors

Start date: June 2010
Phase: N/A
Study type: Interventional

RATIONALE: A breast cancer rehabilitation program and exercise therapy may help improve the quality of life of breast cancer survivors. PURPOSE: This clinical trial studies a breast cancer rehabilitation program in improving quality of life in breast cancer survivors.

NCT ID: NCT01051401 Terminated - Clinical trials for Stage IV Breast Cancer

Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer

Start date: January 2010
Phase: Phase 1
Study type: Interventional

This randomized pilot clinical trial studies rosuvastatin in treating women with cardiovascular complications who are undergoing chemotherapy for breast cancer. Rosuvastatin may prevent or lessen cardiovascular complications in patients undergoing chemotherapy for breast cancer

NCT ID: NCT01050075 Terminated - Breast Cancer Clinical Trials

Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel

Start date: January 2010
Phase: N/A
Study type: Interventional

RATIONALE: Acupuncture may help relieve nerve pain caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well acupuncture works in treating nerve pain in patients with stage I, stage II, and stage III breast cancer who are receiving paclitaxel.

NCT ID: NCT01043003 Completed - Breast Cancer Clinical Trials

Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers

Start date: August 2006
Phase: N/A
Study type: Interventional

RATIONALE: Studying quality-of-life in patients having cancer treatment may identify the intermediate- and long-term effects of treatment on patients with cancer PURPOSE: This randomized clinical trial is studying how well an educational intervention works in supporting Hispanic women with stage I, stage II, or stage III breast cancer and their families or caregivers.

NCT ID: NCT01013337 Completed - Breast Cancer Clinical Trials

Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain

Start date: May 2009
Phase: N/A
Study type: Interventional

RATIONALE: Acupuncture may help relieve moderate or severe joint pain caused by aromatase inhibitors. PURPOSE: This randomized phase II trial is studying acupuncture in treating women with stage I, stage II, or stage III breast cancer with aromatase inhibitor-related joint pain.

NCT ID: NCT00986609 Completed - Breast Cancer Clinical Trials

MUC1 Vaccine for Triple-negative Breast Cancer

Start date: August 19, 2009
Phase: Early Phase 1
Study type: Interventional

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. PURPOSE: To evaluate the efficacy of poly-ICLC + MUCI peptide vaccine in boosting the immunologic response to MUCI in patients with triple-negative BC

NCT ID: NCT00795769 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Start date: August 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients undergoing stem cell transplant.

NCT ID: NCT00679029 Terminated - Clinical trials for Stage IIIA Breast Cancer

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Start date: May 2, 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying the side effects and how well giving combination chemotherapy together with bevacizumab works in treating women with HER2/neu-negative stage II or stage III breast cancer